Parallax Volatility Advisers’s Charles River Laboratories CRL Stock Holding History

Parallax Volatility Advisers’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-1,300	Closed	-$269K	–	2062
2024 Q2	$269K	Hold	1,300	–	–	﹤0.01%	1565
2024 Q1	$352K	Sell	1,300 -2,200	-63%	-$525K	﹤0.01%	1474
2023 Q4	$827K	Sell	3,500 -800	-19%	-$157K	﹤0.01%	1468
2023 Q3	$843K	Buy	+4,300	New	+$883K	﹤0.01%	1426
2022 Q4	–	Sell	-1,000	Closed	-$196K	–	2939
2022 Q3	$196K	Buy	+1,000	New	+$216K	﹤0.01%	2317
2022 Q2	–	Sell	-900	Closed	-$256K	–	2947
2022 Q1	$256K	Buy	+900	New	+$278K	﹤0.01%	2103
2021 Q4	–	Sell	-200	Closed	-$83K	–	3071
2021 Q3	$83K	Buy	+200	New	+$83.1K	﹤0.01%	2639
2021 Q1	–	Sell	-70,000	Closed	-$17.5M	–	3298
2020 Q4	$17.5M	Sell	70,000 -44,000	-39%	-$10.5M	0.01%	825
2020 Q3	$25.8M	Buy	+114,000	New	+$23.7M	0.02%	637
2019 Q2	–	Sell	-40,000	Closed	-$5.81M	–	2666
2019 Q1	$5.81M	Buy	+40,000	New	+$5.26M	0.01%	643

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return

Parallax Volatility Advisers's CRL Position: Q1 2024 in Review

Parallax Volatility Advisers sold out of Charles River Laboratories (CRL) in Q1 2024, closing a stake of 80 shares — an estimated $19.1K sold.

Parallax Volatility Advisers first reported a position in CRL in Q1 2019 and held it in 6 quarters. The position peaked at $8.24M in Q4 2020. 676 funds tracked by Wall St. Rank hold CRL as of Q1 2024.

Parallax Volatility Advisers reported no remaining Charles River Laboratories position as of Q1 2024 after selling out during the quarter.
Parallax Volatility Advisers sold 80 Charles River Laboratories shares in Q1 2024, an estimated $19.1K.
Parallax Volatility Advisers first reported a position in Charles River Laboratories in Q1 2019 and held it in 6 quarters.
Parallax Volatility Advisers's Charles River Laboratories position peaked at $8.24M in Q4 2020.
676 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2024.

Based on Parallax Volatility Advisers's 13F filing for Q1 2024, filed 15 May 2024.